EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preparative Biocatalytic Synthesis of α-Ketomethylselenobutyrate—A Putative Agent for Cancer Therapy

Maksim V Nikulin iD, Viktor V Drobot, Yevgeniya I Shurubor iD, Vytas K Švedas iD, Boris F Krasnikov iD

Molecules · 2023

DOI: 10.3390/molecules28176178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Maksim V Nikulin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Belozersky Institute of Physicochemical Biology, Lomonosov Moscow State University, Lenin Hills 1, Bldg. 40, Moscow 119991, Russia. Hauptthemen laut MEDLINE: Biomedical Research, Neoplasms. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Federal Medical Biological Agency (FMBA) of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biomedical studies of the role of organic selenium compounds indicate that the amino acid derivative of L-selenomethionine, α-ketomethylselenobutyrate (KMSB), can be considered a potential anticancer therapeutic agent. It was noted that, in addition to a direct effect on redox signaling molecules, α-ketoacid metabolites of organoselenium compounds are able to change the status of histone acetylation and suppress the activity of histone deacetylases in cancer cells. However, the wide use of KMSB in biomedical research is hindered not only by its commercial unavailability, but also by the fact that there is no detailed information in the literature on possible methods for the synthesis of this compound. This paper describes in detail the procedure for obtaining a high-purity KMSB preparation (purity ≥ 99.3%) with a yield of the target product of more than 67%. L-amino acid oxidase obtained from C. adamanteus was used as a catalyst for the conversion of L-selenomethionine to KMSB. If necessary, this method can be used as a basis both for scaling up the synthesis of KMSB and for developing cost-effective biocatalytic technologies for obtaining other highly purified drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomedical ResearchNeoplasmsSelenomethionineBiocatalysisAcetylationAntioxidants

Stichwörter der Autor:innen

L-amino acid oxidasecancer therapyhistone deacetylase inhibitionorganoselenium compoundspreparative biocatalytic synthesisα-ketomethylselenobutyrate

Substanzen

SelenomethionineAntioxidants

Autor:innen und Institutionen

  • Belozersky Institute of Physicochemical Biology, Lomonosov Moscow State University, Lenin Hills 1, Bldg. 40, Moscow 119991, Russia.
  • Centre for Strategic Planning of FMBA of the Russian Federation, Pogodinskaya St., Bldg. 10, Moscow 119121, Russia.
  • Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Lenin Hills 1, Bldg. 73, Moscow 119991, Russia.

ORCID-Profile: Maksim V Nikulin, Yevgeniya I Shurubor, Vytas K Švedas, Boris F Krasnikov

Förderung

  • Federal Medical Biological Agency (FMBA) of the Russian Federation

Zitieren

APA

Nikulin, M. V., Drobot, V. V., Shurubor, Y. I., Švedas, V. K., & Krasnikov, B. F. (2023). Preparative Biocatalytic Synthesis of α-Ketomethylselenobutyrate—A Putative Agent for Cancer Therapy. Molecules. https://doi.org/10.3390/molecules28176178

Vancouver

Nikulin MV, Drobot VV, Shurubor YI, Švedas VK, Krasnikov BF. Preparative Biocatalytic Synthesis of α-Ketomethylselenobutyrate—A Putative Agent for Cancer Therapy. Molecules. 2023. doi:10.3390/molecules28176178

BibTeX
@article{Nikulin2023,
  author = {Nikulin, Maksim V and Drobot, Viktor V and Shurubor, Yevgeniya I and Švedas, Vytas K and Krasnikov, Boris F},
  title = {Preparative Biocatalytic Synthesis of α-Ketomethylselenobutyrate—A Putative Agent for Cancer Therapy},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28176178}
}
Kostenlos starten →